Gilead Sciences, Inc. $GILD is AustralianSuper Pty Ltd’s 9th Largest Position

AustralianSuper Pty Ltd reduced its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 10.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,034,089 shares of the biopharmaceutical company’s stock after selling 343,966 shares during the quarter. Gilead Sciences accounts for approximately 1.5% of AustralianSuper Pty Ltd’s holdings, making the stock its 9th biggest holding. AustralianSuper Pty Ltd owned approximately 0.24% of Gilead Sciences worth $336,784,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of the business. GoalVest Advisory LLC boosted its holdings in Gilead Sciences by 7,566.7% during the 2nd quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 227 shares during the period. Corundum Trust Company INC purchased a new stake in Gilead Sciences in the third quarter worth $26,000. Harbor Asset Planning Inc. bought a new stake in shares of Gilead Sciences during the second quarter worth $27,000. Putney Financial Group LLC lifted its position in shares of Gilead Sciences by 53.4% during the second quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 94 shares during the last quarter. Finally, Howard Hughes Medical Institute purchased a new stake in shares of Gilead Sciences during the second quarter valued at $30,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently commented on GILD shares. JPMorgan Chase & Co. raised their price target on shares of Gilead Sciences from $145.00 to $150.00 and gave the stock an “overweight” rating in a research note on Friday, October 31st. The Goldman Sachs Group upped their target price on shares of Gilead Sciences from $110.00 to $115.00 and gave the stock a “neutral” rating in a research note on Thursday, January 8th. Daiwa Capital Markets raised their target price on shares of Gilead Sciences from $128.00 to $129.00 and gave the stock an “outperform” rating in a research report on Thursday, November 13th. Scotiabank began coverage on Gilead Sciences in a report on Thursday, November 13th. They issued a “sector outperform” rating and a $140.00 price target for the company. Finally, Royal Bank Of Canada increased their price objective on Gilead Sciences from $100.00 to $103.00 and gave the stock a “sector perform” rating in a research note on Tuesday, January 20th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Gilead Sciences presently has an average rating of “Moderate Buy” and a consensus target price of $135.36.

Insider Activity

In related news, insider Johanna Mercier sold 3,000 shares of the firm’s stock in a transaction dated Thursday, January 15th. The stock was sold at an average price of $124.31, for a total transaction of $372,930.00. Following the sale, the insider owned 103,221 shares of the company’s stock, valued at $12,831,402.51. This trade represents a 2.82% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Jeffrey Bluestone sold 5,000 shares of Gilead Sciences stock in a transaction dated Tuesday, January 20th. The shares were sold at an average price of $123.50, for a total value of $617,500.00. Following the completion of the transaction, the director owned 8,920 shares in the company, valued at $1,101,620. This trade represents a 35.92% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 247,397 shares of company stock worth $31,986,612 over the last ninety days. 0.27% of the stock is currently owned by corporate insiders.

Gilead Sciences Stock Performance

Shares of GILD stock opened at $139.72 on Thursday. The firm has a market cap of $173.35 billion, a price-to-earnings ratio of 21.66, a PEG ratio of 0.74 and a beta of 0.33. Gilead Sciences, Inc. has a 52-week low of $93.37 and a 52-week high of $141.71. The company has a quick ratio of 1.31, a current ratio of 1.45 and a debt-to-equity ratio of 1.03. The company’s 50 day moving average is $124.76 and its 200 day moving average is $119.24.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.16 by $0.31. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The business had revenue of $7.77 billion for the quarter, compared to analysts’ expectations of $7.42 billion. During the same quarter last year, the firm earned $2.02 EPS. The business’s revenue for the quarter was up 3.0% on a year-over-year basis. On average, sell-side analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences News Roundup

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Phase‑3 Trodelvy combo beat Keytruda + chemo in a pivotal study, sparking a sharp rally and renewed bullish debate about Gilead’s oncology upside. Gilead Sciences (GILD) Is Up 11.0% After Trodelvy Combo Outperforms Keytruda Chemo In Phase 3 Trial
• Positive Sentiment: Multiple analyst upgrades/price‑target raises (Citigroup to $156, Truist, BMO, UBS commentary) are reinforcing buy-side momentum and likely supporting higher valuations in the near term. Citigroup adjusts price target on Gilead Sciences to 156 from 140; maintains buy rating
• Neutral Sentiment: Gilead will report Q4 & full‑year 2025 results on Feb 10 — a clear near‑term catalyst that could amplify either the positive trial reaction or reveal operational headwinds. Gilead Sciences to Release Fourth Quarter & Full Year 2025 Financial Results on Tuesday, February 10, 2026
• Neutral Sentiment: News aggregator and investor‑attention pieces (Zacks, sector writeups) are boosting visibility but are not new fundamental information. Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
• Neutral Sentiment: Short‑interest data in the feed shows zero shares/NaN (likely a reporting artifact) — not a reliable signal for positioning or squeeze risk today.
• Negative Sentiment: CEO Daniel O’Day sold 115,640 shares (~$15.6M) in late January, reducing his holding ~17% — a notable insider sale that market participants may view as a short‑term negative or liquidity event. SEC filing: Form 4 — Daniel Patrick O’day sale

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.